Aktis Oncology
Biotechnology company pioneering targeted alpha radiopharmaceuticals for solid tumor cancers.
Website: https://www.aktisoncology.com/
Cover Block
PUBLIC
| Name | Aktis Oncology |
| Tagline | Biotechnology company pioneering targeted alpha radiopharmaceuticals for solid tumor cancers. |
| Headquarters | Boston, United States |
| Founded | 2020 |
| Stage | Public |
| Business Model | Other |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | $100M+ (total disclosed ~$474M) |
Links
PUBLIC
- Website: https://www.aktisoncology.com/
- LinkedIn: https://www.linkedin.com/company/aktis-oncology
Executive Summary
PUBLIC
Aktis Oncology is a clinical-stage biotechnology company that has positioned itself at the forefront of targeted alpha radiotherapy for solid tumors. The field attracts significant capital and strategic interest from large pharmaceutical companies [MedCity News, Jan 2026]. Founded and incubated by venture firm MPM Capital in 2020, the company emerged from stealth in 2021 with a $72 million Series A round. That round included strategic investments from Novartis and Bristol Myers Squibb. These moves signal early validation from industry leaders [Aktis Oncology, Unknown].
Its core proposition is a proprietary miniprotein radioconjugate platform. The platform delivers potent alpha-emitting isotopes directly to tumors. It aims to combine high tumor-killing efficacy with a favorable safety profile by minimizing off-target exposure [Aktis Oncology, Unknown].
Leadership is anchored by CEO Matthew Roden, PhD. Along with founding COO Brian Goodman, PhD, and CSO Paul L. Feldman, PhD, he brings deep drug development experience to advancing a novel therapeutic modality [Aktis Oncology, Unknown]. The company's business model mixes proprietary pipeline development and strategic partnerships. A collaboration with Eli Lilly exemplifies this. It included a $60 million upfront payment and potential milestone payments of up to $1.1 billion [Goodwin, May 2024].
This approach, coupled with a $318 million IPO in January 2026, provides substantial capital. The IPO advances lead candidate AKY-1189. The asset has entered Phase 1b trials and received FDA Fast Track Designation [BioPharma Dive, Jan 2026] [Aktis Oncology, Feb 2026].
Over the next 12-18 months, the key inflection point will be the clinical readout from the ongoing Phase 1b trial. That readout will provide the first human efficacy and safety data for its platform. It will validate technical differentiation in a crowded radiopharma landscape.
Data Accuracy: YELLOW -- Key facts (founding, funding, IPO, partnerships) are corroborated by multiple sources, but some team details and early-stage funding specifics rely on single-source company statements.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Public |
| Business Model | Other (Biotech/Therapeutics) |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding | $100M+ (total disclosed ~$156M) |
Company Overview
PUBLIC
Aktis Oncology was founded and incubated in 2020 by the venture capital firm MPM Capital. It emerged from stealth the following year with a substantial Series A financing [MedCity News, Jan 2026]. The company operates as a clinical-stage biotechnology entity. Its headquarters are in Boston, Massachusetts. It has a research facility in Durham, North Carolina [Aktis Oncology].
Its founding thesis centered on applying the high-energy, short-range properties of alpha particle radiation to solid tumors. This class of cancers has been historically difficult to treat with existing radiopharmaceuticals [Aktis Oncology].
The company's development timeline is marked by capital and strategic milestones. It followed its initial $72 million Series A round with an $84 million extension. That round included participation from Novartis and Bristol Myers Squibb [Crunchbase News] [MedCity News, Jan 2026]. In May 2024, it entered a significant collaboration with Eli Lilly. That deal brought a $60 million upfront payment for a multi-target discovery program [Goodwin, May 2024].
The company completed an upsized IPO in January 2026. It raised $318 million and became the first biotech IPO of that year [BioPharma Dive, Jan 2026] [IPOScoop, Jan 2026].
Key operational milestones include long-term supply agreements for Actinium-225 with NorthStar, Niowave, and TerraPower [PRNewswire, 2022]. In early 2026, lead candidate AKY-1189 received U.S. FDA Fast Track Designation. It also initiated a Phase 1b clinical trial across multiple tumor types [Aktis Oncology, Feb 2026].
Data Accuracy: GREEN -- Confirmed by company press releases, Crunchbase, and multiple third-party news reports.
Product and Technology
MIXED
Aktis Oncology's core asset is a proprietary, isotope-agnostic miniprotein radioconjugate platform. It generates molecules that selectively deliver alpha-emitting radioisotopes to solid tumors [Aktis Oncology].
The public framing emphasizes high tumor penetration and rapid clearance from healthy tissues. This aims to maximize therapeutic effect while minimizing off-target toxicity [Aktis Oncology]. The platform produces a pipeline of candidates. Lead program AKY-1189 targets Nectin-4-expressing cancers in a Phase 1b clinical trial [Aktis Oncology].
The platform differentiates through engineered miniproteins as targeting agents. These are smaller than traditional antibodies. The company claims this allows deeper penetration into dense solid tumors [Aktis Oncology].
A key feature is the isotope-agnostic nature. It lets clinicians use an imaging isotope to confirm target engagement before a therapeutic alpha-emitter like Actinium-225 [Aktis Oncology]. This "see before you treat" capability could address a clinical challenge if validated.
The company has secured Actinium-225 supply through agreements with NorthStar, Niowave, and TerraPower [Aktis Oncology].
Beyond the internal pipeline, a Eli Lilly collaboration validates the platform. Announced in May 2024, the deal includes a $60 million upfront payment. Potential milestone payments reach up to $1.1 billion for radiopharmaceuticals against Lilly-selected targets [Goodwin, May 2024].
This partnership extends utility outside Aktis's proprietary focus. The most advanced milestone is FDA Fast Track Designation for AKY-1189 in February 2026. This expedites development and review for serious conditions [Aktis Oncology, Feb 2026].
Data Accuracy: YELLOW -- Platform and pipeline details are sourced from company materials; the Lilly collaboration terms are reported by a law firm involved in the transaction. Clinical trial status and FDA designation are from company press releases.
Market Research and Opportunity
PUBLIC The radiopharmaceutical market gains momentum as a platform technology. It addresses prevalent solid tumors difficult to treat with systemic radiation.
Quantifying the total addressable market for targeted alpha therapies requires segmentation. Third-party analysts project the broader radiopharmaceutical therapeutics market at $8.5 billion to $13.5 billion by 2030 [Grand View Research, 2024].
Aktis focuses on solid tumors like breast, lung, colorectal, bladder, and liver cancers. This targets a larger patient population than prostate cancer indications that validated the category. A precise serviceable addressable market for its miniprotein platform lacks public modeling. The Eli Lilly collaboration, valued at up to $1.1 billion in milestones [Goodwin, May 2024], benchmarks early-stage platform value.
The primary demand driver is unmet need in oncology. Solid tumors resist current radiopharmaceuticals that use antibodies with poor penetration and slow clearance [Aktis Oncology]. Platforms like Aktis's seek high specificity and rapid clearance.
A secondary tailwind is large pharmaceutical companies securing radiopharmaceutical capabilities. Multi-billion dollar acquisitions validate the category. They create exit potential for platform innovators before late-stage data.
Key adjacent markets include antibody-drug conjugates and small molecule inhibitors. Radiopharmaceuticals may combine with these. The regulatory and reimbursement landscape for novel radiopharmaceuticals remains complex compared to traditional pharmaceuticals.
Data Accuracy: YELLOW -- Market sizing is based on analogous third-party reports for the broader radiopharmaceutical category. The Eli Lilly collaboration value is cited from a single legal industry source.
Competitive Landscape
MIXED
Aktis Oncology competes in targeted radiopharmaceuticals. The battle centers on platform differentiation and clinical validation [Aktis Oncology]. Its positioning relies on the miniprotein platform for alpha radiotherapy in solid tumors. This segment lacks service from earlier approaches.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Aktis Oncology | Miniprotein platform for alpha radiotherapy in solid tumors | Public, $318M IPO (Jan 2026) | Isotope-agnostic platform; strategic collaboration with Eli Lilly | [Aktis Oncology], [MedCity News, Jan 2026] |
| RayzeBio | Targeted radiopharmaceuticals (Ac-225) | Acquired by Bristol Myers Squibb (2024) | Focus on Actinium-225 pipeline; integrated into large pharma | [Crunchbase] |
| Fusion Pharmaceuticals | Next-generation radiopharmaceuticals | Public, acquired by AstraZeneca (2024) | Proprietary alpha-emitting platform (FPI) and manufacturing capabilities | [Crunchbase] |
| Point Biopharma | Radiopharmaceuticals for cancer | Acquired by Eli Lilly (2023) | Clinical-stage pipeline and manufacturing scale | [Crunchbase] |
| Mariana Oncology | Precision radiopharmaceuticals | Acquired by Novartis (2024) | Peptide-based targeting platform | [Crunchbase] |
The competitive map has two tiers. Platform-focused biotechs like RayzeBio (Bristol Myers Squibb), Fusion (AstraZeneca), Point (Eli Lilly), and Mariana (Novartis) form the first [Crunchbase]. These acquisitions validate radiopharma. They also create resourced competitors.
Independent clinical-stage companies like Aktis form the second tier. They compete for talent, sites, and attention against pharma subsidiaries.
Aktis's defensible edge is its miniprotein platform and Eli Lilly collaboration. The platform offers isotope flexibility for imaging and therapy [Aktis Oncology]. The deal provides $60 million upfront and up to $1.1 billion milestones. It validates discovery for non-core targets [Goodwin, May 2024].
This edge endures if trials show clinical advantages. It fades if competitors match efficacy faster.
The early clinical stage exposes Aktis most. AKY-1189 is in Phase 1b [Aktis Oncology]. Competitors have later-stage assets with pharma resources.
Reliance on external isotope partnerships introduces execution risk. Agreements with NorthStar, Niowave, and TerraPower mitigate this [PRNewswire, 2022]. Vertically integrated rivals avoid it.
The 18-month scenario depends on data. Strong Phase 1b results for AKY-1189 in solid tumors could position Aktis as a leading platform. It might draw partnerships. Weak data risks consolidation around pharma acquirers.
Data Accuracy: YELLOW -- Competitor positioning and acquisition status are confirmed via Crunchbase. Aktis's collaboration terms are cited from a law firm release. Platform differentiation claims are sourced from the company.
Opportunity
PUBLIC
If the platform proves effective in clinic, Aktis Oncology could capture a multi-billion dollar opportunity. Targeted alpha radiotherapy would reach underserved solid tumor populations.
The headline opportunity is category leadership in solid tumor oncology. The miniprotein radioconjugate platform works across isotopes and targets [Aktis Oncology]. Early pharma validation supports a path beyond one drug.
The Eli Lilly collaboration exceeds $1.1 billion. It includes $60 million upfront for target discovery [Goodwin, May 2024]. The $318 million IPO funds internal pipeline [BioPharma Dive, Jan 2026]. This dual strategy marks platform leaders.
Growth follows concrete scenarios with catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Lead Asset Breakthrough | AKY-1189 demonstrates compelling efficacy in Phase 1b/2 trials, leading to accelerated approval for a major tumor type like bladder or lung cancer. | Positive interim clinical readout for AKY-1189, supported by its FDA Fast Track designation [Aktis Oncology, Feb 2026]. | The Fast Track designation indicates the FDA recognizes the potential to address an unmet need, potentially streamlining the development path. The company has secured its Actinium-225 supply, a critical execution component [PRNewswire, 2022]. |
| Platform Partnership Expansion | The success of the Lilly collaboration triggers similar multi-target deals with other large pharma companies, turning Aktis into a central discovery engine for the industry. | Announcement of a second major pharma collaboration on different target sets. | The structure of the Lilly deal,$60M upfront for rights to products on a defined target set,creates a replicable blueprint [Goodwin, May 2024]. Early investors like Novartis, Bristol Myers Squibb, and Merck provide a natural network of potential partners [MedCity News, Jan 2026]. |
| Pipeline Proliferation | The platform efficiently generates multiple clinical candidates, transforming Aktis into a fully integrated radiopharma company with a broad oncology portfolio. | IND filings for a second and third wholly-owned candidate from the platform. | The company's research operations in both Boston and Research Triangle Park suggest dedicated discovery capacity [Aktis Oncology]. The IPO capital is explicitly for advancing the pipeline [BioPharma Dive, Jan 2026]. |
Compounding builds a data flywheel. Trials generate data on miniprotein behavior in tumors. This de-risks future candidates [Aktis Oncology].
The platform enables imaging before therapy. This refines targeting [Aktis Oncology]. Multi-producer Actinium-225 agreements create an operational moat [PRNewswire, 2022].
Recent deals frame the win size. Bristol Myers Squibb acquired RayzeBio for $4.1 billion [Various].
A lead breakthrough could yield low-to-mid single-digit billion valuation. Partnership expansion supports discovery engine value. These illustrate upside if technology succeeds clinically.
Data Accuracy: YELLOW -- Key opportunity elements (platform strategy, collaboration terms) are confirmed by company and legal sources, but clinical catalyst timing and competitive valuation benchmarks are inferred from sector dynamics.
Sources
PUBLIC
[Aktis Oncology, Unknown] AKTIS ONCOLOGY ANNOUNCES $72M SERIES A FINANCING TO ADVANCE BREAKTHROUGH RADIOPHARMACEUTICALS TO TREAT SOLID TUMORS | https://www.aktisoncology.com/news/aktis-oncology-announces-72m-series-a-financing-to-advance-breakthrough-radiopharmaceuticals-to-treat-solid-tumors/
[Aktis Oncology] Platform | Aktis Oncology | https://www.aktisoncology.com/platform/
[Aktis Oncology] Contact Us | Aktis Oncology | https://www.aktisoncology.com/contact-us/
[Aktis Oncology, Feb 2026] Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate | https://investors.aktisoncology.com/news-releases/news-release-details/aktis-oncology-receives-us-fda-fast-track-designation-aky-1189
[MedCity News, Jan 2026] Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals | https://medcitynews.com/2026/01/aktis-oncology-ipo-miniprotein-radiopharmaceutical-cancer-radiation-akts/
[Crunchbase News] Aktis Oncology Nabs A Rare Upround of $84M | https://news.crunchbase.com/health-wellness-biotech/aktis-cancer-startup/
[Goodwin, May 2024] Aktis Oncology enters into Strategic Collaboration with Lilly | https://www.pappas-capital.com/aktis-oncology-enters-into-strategic-collaboration-with-lilly/
[BioPharma Dive, Jan 2026] Aktis raises $318M in 2026’s first biotech IPO | https://www.biopharmadive.com/news/aktis-biotech-ipo-radiopharmaceutical-cancer/809066/
[IPOScoop, Jan 2026] Aktis Oncology Announces Pricing of its Upsized Initial Public Offering | https://investors.aktisoncology.com/news-releases/news-release-details/aktis-oncology-announces-pricing-its-upsized-initial-public
[PRNewswire, 2022] Aktis Oncology Announces Actinium-225 Supply Agreements with Leading Isotope Producers | https://www.prnewswire.com/news-releases/aktis-oncology-announces-actinium-225-supply-agreements-with-leading-isotope-producers-301610120.html
[Crunchbase] RayzeBio, Fusion Pharmaceuticals, Point Biopharma, Mariana Oncology - Crunchbase | https://www.crunchbase.com/
[Grand View Research, 2024] Radiopharmaceuticals Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/radiopharmaceuticals-market
Articles about Aktis Oncology
- Aktis Oncology Lands a $318M IPO for Its Alpha Particle Bet on Solid Tumors — The biotech's lead candidate is in Phase 1b trials for a range of cancers, with a key Eli Lilly deal and a secured supply of the rare isotope Actinium-225.